Effects of a transdermal testosterone metered-dose nanoemulsion in peri- and postmenopausal women: a novel protocol for treating low libido

• Main Authors: Marco Antonio Botelho, Dinalva Brito Queiroz, Celso Felício Carvalho, Allan Freitas, Gisele Barros, Julia Gouvea, Lia Patrus, Mariane Bannet, Amália Cinthia Rego, Irami Araújo-Filho, Ivaldo Silva
• Format: Article
• Language: English
• Published: Mavera, Edições Científicas e Técnicas Ltda
• Series: Medical Express
• Subjects: deficiência androgênica; menopausa; nanotecnologia; via transdérmica; testosterona; nanopartículas
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292015000500003&lng=en&tlng=en

OBJECTIVE: To investigate the efficacy of a transdermal nanoemulsion testosterone associated with transdermal estrogen therapy as a novel protocol treatment for emergent loss of libido. METHODS: Twenty-four women, aged 31-75 years (mean age, 51.7), with emergent loss of libido were allocated to treatment with a novel transdermal formulation of 500 µg/day of testosterone (Biolipid/B2®-testosterone) for 12 weeks, as part of an open label prospective study on peri- and post-menopausal women. Subjects applied the formulation on the right forearm. Clinical and laboratorial parameters including the sexual complaints; serum concentrations of testosterone, insulin, C-reactive protein, weight, blood pressure; body mass index and waist circumference were compared between baseline and 12 weeks after treatment. RESULTS: The mean total serum testosterone increased significantly (p = 0.009) after 12 weeks of treatment. No adverse or androgenic events were observed. There were positive and significant differences (p < 0.05) on sexual complaints, blood pressure, body mass index and waist circumference after transdermal nanoemulsion testosterone treatment. CONCLUSION: This protocol is effective in increasing testosterone levels in peri- and postmenopausal women with low libido.